Literature DB >> 35543887

Spread of lymph node metastasis and adjuvant therapy for distal cholangiocarcinoma.

Hiroshi Kurahara1, Yuko Mataki2, Tetsuya Idichi2, Yota Kawasaki2, Shinichiro Mori2, Ken Sasaki2, Takaaki Arigami2, Akihiro Nakajo2, Yoshihiko Fukukura3, Michiyo Higashi4, Takao Ohtsuka2.   

Abstract

BACKGROUND: Lymphatic metastasis is a major route of metastasis in distal cholangiocarcinoma (DCC). The present study aimed to elucidate the pattern of lymph node (LN) metastasis and the effectiveness of LN dissection and postoperative adjuvant chemotherapy in patients with DCC.
METHODS: Patients who underwent surgical resection with curative intent for DCC were enrolled. The nomenclature of the LN stations was defined according to the Japanese Society of Hepato-Biliary-Pancreatic Surgery guidelines. Effectiveness of LN dissection of each station was calculated using frequency of LN metastasis to the station and 5-year survival rate of patients with LN metastasis to that station.
RESULTS: Of the 105 patients included in the study, 46 (43.8%) had LN metastasis, and 43 (41.0%) underwent postoperative adjuvant therapy. LN metastasis, serum carbohydrate antigen (CA) 19-9 level > 37 U/mL, and positive bile duct margin were independent risk factors for shorter overall survival (OS). The most common metastatic LN station at surgery was No. 13 (32.7%), followed by No. 12 (19.2%), No. 17 (9.6%), and No. 8 (6.6%). There was no effectiveness of LN dissection of the station No. 8, 14, and 16. Adjuvant chemotherapy was significantly associated with longer OS in patients with LN metastasis but not in those with positive ductal margins or serum CA 19-9 level > 37 U/mL.
CONCLUSIONS: Postoperative adjuvant chemotherapy was associated with a better prognosis in patients with DCC and LN metastasis. However, a more effective therapeutic strategy is required to improve the prognosis of patients with other negative prognostic factors.
© 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.

Entities:  

Keywords:  Bile duct cancer; Effectiveness of lymph node dissection; Efficacy index; Station of lymph node

Mesh:

Substances:

Year:  2022        PMID: 35543887     DOI: 10.1007/s10147-022-02175-z

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  2 in total

1.  8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers.

Authors:  Yun Shin Chun; Timothy M Pawlik; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2017-07-27       Impact factor: 5.344

2.  A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).

Authors:  Osamu Itano; Yusuke Takemura; Norihiro Kishida; Eiji Tamagawa; Hiroharu Shinozaki; Ken Ikeda; Hidejiro Urakami; Shigenori Ei; Shigeo Hayatsu; Keiichi Suzuki; Tadayuki Sakuragawa; Masatsugu Ishii; Masaya Shito; Koichi Aiura; Hiroto Fujisaki; Kiminori Takano; Junichi Matsui; Takuya Minagawa; Masahiro Shinoda; Minoru Kitago; Yuta Abe; Hiroshi Yagi; Go Oshima; Shutaro Hori; Yuko Kitagawa
Journal:  BMC Cancer       Date:  2020-07-23       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.